Acadia Pharmaceuticals (NASDAQ: ACAD) reported an insider sale by Executive Vice President and Chief Financial Officer Mark C. Schneyer, who disposed of 7,385 shares of common stock between March 25 and March 26, 2026. The sales were executed at prices ranging from $21.47 to $21.7174 and produced aggregate proceeds of roughly $159,135. The companys shares are trading at $21.47, reflecting a year-to-date decline of about 20% and a 25% gain over the prior 12 months.
The filings indicate the disposition was undertaken to satisfy withholding taxes and other tax-related obligations imposed by Acadia in connection with the vesting of restricted stock units (RSUs). Separately, on March 24 and March 25 Schneyer received a total of 14,316 shares of Acadia common stock as the RSUs vested.
Transaction details
- Seller: Mark C. Schneyer, Executive Vice President and CFO.
- Shares sold: 7,385.
- Sale dates: March 25-26, 2026.
- Price range: $21.47 to $21.7174 per share.
- Proceeds: Approximately $159,135.
- Shares acquired via vesting: 14,316 on March 24 and March 25, 2026.
- Stated purpose of sales: To cover withholding taxes and tax-related items tied to RSU vesting.
Corporate developments and analyst activity
In addition to the insider activity, Acadia announced its most recent earnings and revenue results. Around the same time, BofA Securities updated its coverage of the company, moving its recommendation to a Buy from Neutral while holding a $29 price target. BofA said the recent share price decline was driven by macro factors rather than changes to Acadias fundamentals. The firm did, however, lower its previous price target from $31 to $29 following an internal pipeline review and a recent setback in the European Union.
The EU development involved the European Medicines Agencys Committee for Medicinal Products for Human Use issuing a negative opinion on Acadias Marketing Authorization Application for trofinetide, a candidate therapy for Rett syndrome. The committee cited concerns about the treatments effect size and its limited capture of core symptoms.
Governance changes were also disclosed: Jonathan M. Poole was appointed to Acadias board of directors and to the audit committee, with his term set to expire in 2027. Together, the insider transaction, regulatory feedback and analyst revisions underscore a period of strategic and regulatory developments for the company.